4FR Stock Overview
Operates as a clinical stage drug discovery and development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Faron Pharmaceuticals Oy Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.76 |
| 52 Week High | UK£4.20 |
| 52 Week Low | UK£1.04 |
| Beta | 0.33 |
| 11 Month Change | -29.96% |
| 3 Month Change | -10.94% |
| 1 Year Change | -42.36% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4FR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.7% | -1.9% | -0.2% |
| 1Y | -42.4% | -17.2% | 7.8% |
Return vs Industry: 4FR underperformed the German Biotechs industry which returned -17.7% over the past year.
Return vs Market: 4FR underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 4FR volatility | |
|---|---|
| 4FR Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4FR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4FR's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 34 | Juho Jalkanen | www.faron.com |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes.
Faron Pharmaceuticals Oy Fundamentals Summary
| 4FR fundamental statistics | |
|---|---|
| Market cap | €187.78m |
| Earnings (TTM) | -€31.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.9x
P/E RatioIs 4FR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4FR income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €31.61m |
| Earnings | -€31.61m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 897.6% |
How did 4FR perform over the long term?
See historical performance and comparison